In Vivo Effect of Nano NO Plus Capsules on Hypertensive and Atherosclerotic rat Models

Abstract

Hypertension is a significant public health issue that is increasing in prevalence and can have dangerous complications. This atherosclerotic disease occurs due to lifestyle choices, such as being sedentary, eating fast foods, and a lack of physical exercise. Atherosclerosis has gradually become the leading cause of death worldwide. Currently, the trend of using natural products to supplement and replace synthetic drugs is being considered in many places. This study evaluated the antihypertensive and anti-atherosclerosis effects of Nano NO plus capsules on hypertensive and atherosclerotic rat models. The results showed that Nano NO plus given to rats at doses of 420 mg/kg and 840 mg/kg lowered systolic, diastolic, and average blood pressure (BP) without affecting heart rate. Nano NO plus capsules also increased nitric oxide (NO), superoxide dismutase (SOD), glutathione (GSH), and decreased malondialdehyde (MDA) in the rats’ plasma. All of these effects were comparable to those of Losartan at 25 mg/kg. Furthermore, doses of 420 mg/kg and 840 mg/kg reduced blood lipid test indexes, including triglyceride (TG) levels, total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), and atherogenic index (AI). At the same time, Nano NO plus capsules increased the levels of high-density lipoprotein-cholesterol (HDL-C) in the blood and protected against atherosclerotic lesions of the abdominal aorta in the studied rats. These results indicate that Nano NO plus is a potential product to treat hypertension and atherosclerotic.